Beyond [Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.

Abdlkadir AS; Al-Adhami D; Moghrabi S; Sathekge MM; Kreissl M; Estrada-Lobato E; Shi H; Al-Ibraheem A

doi:10.1186/s12885-026-15900-y

← 뒤로

Beyond [Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.

BMC cancer 2026

Abdlkadir AS, Al-Adhami D, Moghrabi S, Sathekge MM, Kreissl M, Estrada-Lobato E, Shi H, Al-Ibraheem A

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Abdlkadir AS, Al-Adhami D, et al. (2026). Beyond [Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.. BMC cancer. https://doi.org/10.1186/s12885-026-15900-y

MLA Abdlkadir AS, et al.. "Beyond [Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.." BMC cancer, 2026.

PMID 41872814

DOI 10.1186/s12885-026-15900-y

같은 제1저자의 인용 많은 논문 (4)

Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis.
Thyroid research 2026
PET imaging and radionuclide therapy in neuroendocrine prostate cancer: a systematic review.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 2025
Short-term Prostate-specific Antigen Pseudoregression Following [ 177 Lu]-Prostate-specific Membrane Antigen Therapy : Tackling Prostate-specific Antigen Decline Limitations in Patient With Metastatic Castration-resistant Prostate Cancer.
Clinical nuclear medicine 2025
Intense fibroblast activation protein inhibitor localization around the site of embolized gastroduodenal artery in a patient with metachronous pancreatic adenocarcinoma: A potential pitfall in positron imaging.
Acta radiologica open 2024